Health and wellness company Hims & Hers, which sells alternatives to weight-loss drugs like Wegovy, is now collaborating with ...

DGRO boasts a low expense ratio, strong liquidity, and a healthy dividend yield. See why I think the fund is a buy.

Furthermore, those diagnosed with marijuana addiction before they were stricken with colon cancer were 24.4 times more likely ...

The FDA’s alert does not prevent Hims Hers Health from continuing to sell the treatment, but it raises questions about the future of these products in the market. The agency has stressed that ...

After UnitedHealth Group (NYSE: UNH) delivered a surprisingly weak first-quarter report last Thursday, its stock price ...

Encompass Health’s robust Q1 earnings and ambitious expansion strategies have propelled its stock to a 52-week high, ...

Shares of Tivic Health Systems, Inc. (NASDAQ: TIVC) are soaring Tuesday after the company announced it held senior-level briefings with White House officials and the U.S. Food and Drug Administration ...

The company is facing a challenging consumer environment as Americans pull back from spending. There are also concerns about ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.85, a high estimate of $68.00, ...

FOXO Technologies Inc. (NYSE American: FOXO) ("FOXO” or the "Company”), today announced that effective 4.01pm Eastern Time, ...

A combination of increasing prices and sector-wide "shrinkflation" has led to more Americans bypassing their favorite — ...

Hims & Hers Health (HIMS) stock declined about 2% yesterday. The fall came after the U.S. Food and Drug Administration (FDA) ...